Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Construction is now underway with the facility scheduled to be operational by 2025
This will be an added advantage for Supriya Lifescience Limited in the European market.
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
Transformation to pure-play Innovative Medicines company nears completion
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
The committee unanimously decided to confer the Lifetime Achievement Award to Kiran Mazumdar-Shaw for her monumental contributions as a global leader in biotechnology innovation and entrepreneurship
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Aster Pharmacy will be operated by GD Assist Limited in Bangladesh.
Subscribe To Our Newsletter & Stay Updated
